Psychology

Therapeutic mechanisms of psilocybin: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression

Mertens, L. J., Wall, M. B., Roseman, L., Demetriou, L., Nutt, D. J., & Carhart-Harris, R. L. | Journal of Psychopharmacology | 16 January 2020

Ayahuasca’s ‘afterglow’: improved mindfulness and cognitive flexibility in ayahuasca drinkers.

Murphy-Beiner, A., & Soar, K. | Psychopharmacology | 11 January 2020

A qualitative descriptive analysis of effects of psychedelic phenethylamines and tryptamine

Palamar, J. J., & Acosta, P. | Clinical and Experimental | 07 January 2020

Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species

Halberstadt, A. L., Chatha, M., Klein, A. K., Wallach, J., & Brandt, S. D. | Neuropharmacology | 7 January 2020

The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis.

Goldberg, S. B., Pace, B. T., Nicholas, C. R., Raison, C. L., & Hutson, P. R. | Psychiatry Research | 2 January 2020

Preliminary Report on the Effects of a Low Dose of LSD on Resting-State Amygdala Functional Connectivity.

Bershad, A. K., Preller, K. H., Lee, R., Keedy, S., Wren-Jarvis, J., Bremmer, M. P., & de Wit, H. | Biological Psychiatry: Cognitive Neuroscience and Neuroimaging | 20 December 2019

Esketamine is approved in Europe for treating resistant major depressive disorder

Mahase, E. | BMJ | 20 December 2019

Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers.

Family, N., Maillet, E. L., Williams, L. T., Krediet, E., Carhart-Harris, R. L., Williams, T. M., ... & Raz, S. | Psychopharmacology | 18 December 2019

Decreased directed functional connectivity in the psychedelic state.

Barnett, L., Muthukumaraswamy, S. D., Carhart-Harris, R. L., & Seth, A. K. | NeuroImage | 17 December 2019

Neurotrophic mechanisms of psychedelic therapy

Corne, R., & Mongeau, R. | Biologie aujourd'hui | 12 December 2019

Neuropharmacological modulation of the aberrant bodily self through psychedelics

Ho, J. T., Preller, K. H., & Lenggenhager, B. | Neuroscience & Biobehavioral Reviews | 6 December 2019

Modulation of Social Cognition via Hallucinogens and “Entactogens”.

Preller, K. H., & Vollenweider, F. X. | Frontiers in Psychiatry | 3 December 2019

Therapeutic use of serotoninergic hallucinogens: A review of the evidence and of the biological and psychological mechanisms.

dos Santos, R. G., & Hallak, J. E. C. | Neuroscience & Biobehavioral Reviews | 3 December 2019

Embedding existential psychology within psychedelic science: reduced death anxiety as a mediator of the therapeutic effects of psychedelics.

Moreton, S. G., Szalla, L., Menzies, R. E., & Arena, A. F. | Psychopharmacology | 29 November 2019

Twenty percent better with 20 micrograms? A qualitative study of psychedelic microdosing self-rapports and discussions on YouTube.

Andersson, M., & Kjellgren, A. | Harm reduction journal | 28 November 2019

Serotonergic hallucinogens/psychedelics could be promising treatments for depressive and anxiety disorders in end-stage cancer.

dos Santos, R. G., Bouso, J. C., & Hallak, J. E. | BMC psychiatry | 28 October 2019

Esketamine Prevents Treatment-Resistant Depression Relapse.

Slomski, A. | Jama | 22 October 2019

The ethics of psychedelic research in disorders of consciousness.

Peterson, A., Tagliazucchi, E., & Weijer, C. | Neuroscience of Consciousness | 9 October 2019